Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Cardiff Oncology Inc (NASDAQ: CRDF) was $4.05 for the day, up 1.25% from the previous closing price of $4.00. In other words, the price has increased by $1.25 from its previous closing price. On the day, 0.56 million shares were traded. CRDF stock price reached its highest trading level at $4.13 during the session, while it also had its lowest trading level at $3.94.
Ratios:
Our analysis of CRDF’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.08 and its Current Ratio is at 7.08. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.Robert W. Baird initiated its Outperform rating on December 08, 2021, with a $19 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 269423424 and an Enterprise Value of 179200384. For the stock, the TTM Price-to-Sale (P/S) ratio is 396.22 while its Price-to-Book (P/B) ratio in mrq is 3.25. Its current Enterprise Value per Revenue stands at 262.372 whereas that against EBITDA is -3.714.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.63, which has changed by -0.16837782 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $6.42, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is 0.69%, while the 200-Day Moving Average is calculated to be 32.16%.
Shares Statistics:
CRDF traded an average of 1.25M shares per day over the past three months and 1077760 shares per day over the past ten days. A total of 66.52M shares are outstanding, with a floating share count of 59.79M. Insiders hold about 10.13% of the company’s shares, while institutions hold 34.48% stake in the company. Shares short for CRDF as of 1740700800 were 11382589 with a Short Ratio of 9.10, compared to 1738281600 on 10451856. Therefore, it implies a Short% of Shares Outstanding of 11382589 and a Short% of Float of 17.44.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Cardiff Oncology Inc (CRDF) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.18 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.7 and -$0.95 for the fiscal current year, implying an average EPS of -$0.83. EPS for the following year is -$0.98, with 3.0 analysts recommending between -$0.84 and -$1.08.
